Alvotech was founded in 2013 by the Chairman and CEO, Robert Wessman. His initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland.
Since then, the investment commitment has increased to more than $500 million and Alvotech has established itself as a key player and up-and-coming powerhouse in the biosimilar space.
Meet us at .
Please tell us a little about yourself.